Key Highlights

• Pivotal Phase 3 AURORA Trial Initiated: The global trial evaluates lead candidate CAN-2409 in advanced non-small cell lung cancer patients who failed prior treatment.

• Extensive Global Trial Infrastructure: Parexel is supporting the trial across more than 150 global sites with overall survival as the primary endpoint.

• Healthcare Sector Rotation Tailwind: The XLV healthcare ETF posted its best monthly performance in years as investors shifted from tech into biotech and defensive names.

Candel Therapeutics (NASDAQ: CADL) surged to a fresh 52-week high after announcing the initiation of its global pivotal Phase 3 AURORA trial, evaluating lead candidate aglatimagene besadenovec (CAN-2409) in advanced non-small cell lung cancer patients who failed prior pembrolizumab and platinum chemotherapy.

The trial, supported by Parexel across more than 150 global sites with overall survival as the primary endpoint, marks a critical milestone for the company, representing a major step forward in its clinical development pipeline.

The scale of the trial infrastructure, spanning over 150 global sites, reflects the significant investment and ambition behind the AURORA program as Candel seeks to establish CAN-2409 as a meaningful treatment option for a difficult-to-treat patient population.

The announcement comes amid a broader healthcare sector rotation, with XLV posting its best monthly performance in years as investors shifted from tech into defensive and biotech names, providing a favorable macro backdrop for the company-specific catalyst.

The combination of a major pipeline milestone and a supportive sector rotation has positioned Candel Therapeutics as one of the more notable biotech beneficiaries of the broader shift in investor capital allocation during this period.

()